Related Experiment Video

Updated: May 5, 2026

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

4.3K

Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C

Walter H Hörl1, Alice Schmidt1

  • 1Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|November 30, 2013
PubMed

Insights

Hepatitis C virus (HCV) suppresses hepcidin, a key protein for iron regulation, worsening liver disease. Antiviral therapy can restore hepcidin, but caution with iron is advised for chronic kidney disease patients.

Area of Science:

  • Hepatology
  • Virology
  • Nephrology

Background:

  • Persistent hepatitis C virus (HCV) infection is a leading cause of chronic liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
  • Chronic hepatitis C (CHC) poses significant challenges for patients with chronic kidney disease (CKD), especially those undergoing hemodialysis.
  • Hepatic iron overload exacerbates liver damage in CHC, while iron depletion demonstrates therapeutic benefits.

Purpose of the Study:

  • To investigate the role of hepcidin in chronic hepatitis C (CHC) patients, particularly those with chronic kidney disease (CKD).
  • To understand how HCV infection affects hepcidin levels and iron metabolism.
  • To evaluate the implications of hepcidin levels for iron supplementation strategies in CHC patients with CKD.

Main Methods:

  • Analysis of serum hepcidin levels and/or cellular hepcidin expression in CHC patients without CKD, HCV-infected animal models, and cell cultures.
  • Assessment of the impact of HCV, reactive oxygen species, growth factors, and transcription factors on hepcidin suppression.
  • Evaluation of hepcidin level changes following antiviral therapy (pegylated interferon-alpha and ribavirin).

Main Results:

  • HCV infection is associated with low serum hepcidin levels and/or cellular hepcidin expression, which are suppressed by HCV and other factors.
  • Antiviral therapy effectively increases hepcidin levels and reduces iron overload in CHC patients.
  • Hepcidin directly inhibits HCV replication via STAT3 activation, and HCV circumvents this by lowering hepcidin.

Conclusions:

  • Low hepcidin levels in CHC patients, potentially exacerbated in CKD, contribute to liver disease progression.
  • Iron supplementation should be avoided in CKD patients with CHC, even if treated with erythropoiesis-stimulating agents, due to potential hepcidin deficiency.
  • Restoring hepcidin levels through antiviral therapy is a potential strategy for managing iron overload and liver disease in CHC.

Keywords:
hepatitis Chepcidinironliver

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

13.1K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.4K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
99
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
49
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
57
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387